Chemistry Department, Université Laval, 1045 Ave de la Médecine, Quebec, QC, G1V 0A6, Canada.
Institut National de Santé Publique du Québec, Centre de Toxicologie du Québec, 945 Avenue Wolfe, Québec, QC, G1V 5B3, Canada.
Anal Bioanal Chem. 2021 Jan;413(1):171-181. doi: 10.1007/s00216-020-02989-8. Epub 2020 Oct 29.
The increasing use of titanium dioxide nanoparticles in daily use consumer products such as cosmetics, personal care products, food additives, and even medicine has led to growing concerns regarding human safety. It would be ideal to track exposure to this emerging nanopollutant, for example through bioassays, however, so far nanoparticle assessment in biological matrices such as urine remains challenging. The lack of data is mainly due to the limitations of the current metrology, but also to the low expected concentration in human samples. In this study, a quantification method for titanium dioxide nanoparticles in urine has been developed and validated following the ISO/CEI 17025:2017 guidelines. The detection limit for titanium dioxide nanoparticle mass concentration by single-particle inductively coupled plasma mass spectrometry (SP-ICP-MS) was 0.05 ng mL. The particle size limit was determined using three different approaches, with the highest calculated limit value approaching 50 nm. Repeatability and reproducibility of 14% and 18% respectively were achieved for particle mass concentration, and 6% for both parameters for particle size determination. Method trueness and recovery were 98% and 84%, respectively.
越来越多的二氧化钛纳米颗粒被应用于日常消费品,如化妆品、个人护理产品、食品添加剂,甚至药品,这引起了人们对其人类安全性的关注。如果能通过生物检测等方法来跟踪这种新兴纳米污染物的暴露情况就好了,然而,目前在尿液等生物基质中评估纳米颗粒仍然具有挑战性。缺乏数据主要是由于当前计量学的局限性,以及人类样本中预期浓度低。在本研究中,按照 ISO/CEI 17025:2017 指南,开发并验证了一种尿液中二氧化钛纳米颗粒的定量方法。采用单颗粒电感耦合等离子体质谱法(SP-ICP-MS)检测二氧化钛纳米颗粒的质量浓度的检测限为 0.05ng mL。通过三种不同的方法确定了粒径限值,计算出的最高限值接近 50nm。分别实现了粒径质量浓度的重复性和再现性为 14%和 18%,粒径测定的重复性和再现性均为 6%。方法准确度和回收率分别为 98%和 84%。